Log in

NASDAQ:ZFGN - Zafgen Stock Price, Forecast & News

$1.30
-0.02 (-1.52 %)
(As of 02/17/2020 06:00 AM ET)
Add
Today's Range
$1.24
Now: $1.30
$1.34
50-Day Range
$1.09
MA: $1.20
$1.48
52-Week Range
$0.62
Now: $1.30
$4.99
Volume92,805 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Zafgen, Inc, a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:ZFGN
CUSIPN/A
WebN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees38
Next Earnings Date3/9/2020 (Estimated)
OptionableOptionable

Receive ZFGN News and Ratings via Email

Sign-up to receive the latest news and ratings for ZFGN and its competitors with MarketBeat's FREE daily newsletter.


Zafgen (NASDAQ:ZFGN) Frequently Asked Questions

What is Zafgen's stock symbol?

Zafgen trades on the NASDAQ under the ticker symbol "ZFGN."

How were Zafgen's earnings last quarter?

Zafgen Inc (NASDAQ:ZFGN) released its earnings results on Wednesday, November, 6th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.27) by $0.03. View Zafgen's Earnings History.

When is Zafgen's next earnings date?

Zafgen is scheduled to release their next quarterly earnings announcement on Monday, March 9th 2020. View Earnings Estimates for Zafgen.

What price target have analysts set for ZFGN?

5 Wall Street analysts have issued twelve-month price targets for Zafgen's shares. Their forecasts range from $0.78 to $17.00. On average, they expect Zafgen's share price to reach $7.70 in the next twelve months. This suggests a possible upside of 491.9% from the stock's current price. View Analyst Price Targets for Zafgen.

What is the consensus analysts' recommendation for Zafgen?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zafgen in the last year. There are currently 5 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Zafgen.

Has Zafgen been receiving favorable news coverage?

Media headlines about ZFGN stock have been trending somewhat positive this week, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Zafgen earned a coverage optimism score of 1.8 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Zafgen.

Are investors shorting Zafgen?

Zafgen saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 823,200 shares, an increase of 58.1% from the January 15th total of 520,800 shares. Based on an average daily volume of 673,400 shares, the short-interest ratio is currently 1.2 days. Currently, 2.5% of the shares of the company are sold short. View Zafgen's Current Options Chain.

What other stocks do shareholders of Zafgen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zafgen investors own include CA (CA), Endologix (ELGX), Energy Transfer LP Unit (ET), SCYNEXIS (SCYX), TG Therapeutics (TGTX), BlackRock (BLK), Fate Therapeutics (FATE), Gilead Sciences (GILD), Micron Technology (MU) and AT&T (T).

Who are Zafgen's key executives?

Zafgen's management team includes the folowing people:
  • Mr. Jeffrey S. Hatfield, CEO & Director (Age 61)
  • Ms. Patricia L. Allen, Chief Financial Officer (Age 57)
  • Dr. Dennis D. Kim M.D., MBA, Chief Medical Officer (Age 49)
  • Dr. James E. Vath, Head of Discovery & Devel. (Age 58)
  • Mr. Brian P. McVeigh, Chief Bus. Officer (Age 46)

Who are Zafgen's major shareholders?

Zafgen's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (6.38%), Russell Investments Group Ltd. (1.06%), Point72 Asset Management L.P. (0.55%), Virtu Financial LLC (0.28%), Wedbush Securities Inc. (0.23%) and Jane Street Group LLC (0.16%). View Institutional Ownership Trends for Zafgen.

Which institutional investors are selling Zafgen stock?

ZFGN stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Wedbush Securities Inc. and State Street Corp. View Insider Buying and Selling for Zafgen.

Which institutional investors are buying Zafgen stock?

ZFGN stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Renaissance Technologies LLC, Russell Investments Group Ltd., Virtu Financial LLC and Jane Street Group LLC. View Insider Buying and Selling for Zafgen.

How do I buy shares of Zafgen?

Shares of ZFGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Zafgen's stock price today?

One share of ZFGN stock can currently be purchased for approximately $1.30.


MarketBeat Community Rating for Zafgen (NASDAQ ZFGN)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  337 (Vote Outperform)
Underperform Votes:  308 (Vote Underperform)
Total Votes:  645
MarketBeat's community ratings are surveys of what our community members think about Zafgen and other stocks. Vote "Outperform" if you believe ZFGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZFGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/17/2020 by MarketBeat.com Staff

Featured Article: Why do commodities matter?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel